Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease

Katsutoshi Furukawa, Naoki Tomita, Daisuke Uematsu, Kazunori Okahara, Hiroyuki Shimada, Masaki Ikeda, Toshifumi Matsui, Koichi Kozaki, Masahiko Fujii, Tatsuji Ogawa, Hiroyuki Umegaki, Katsuya Urakami, Hiroshi Nomura, Naoto Kobayashi, Aki Nakanishi, Yukihiro Washimi, Hisashi Yonezawa, Satoshi Takahashi, Masaharu Kubota, Yosuke WakutaniDaisuke Ito, Takahiro Sasaki, Etsuro Matsubara, Kaori Une, Aiko Ishiki, Yukie Yahagi, Mikio Shoji, Hiroyasu Sato, Yasuo Terayama, Masafumi Kuzuya, Nobuo Araki, Manabu Kodama, Takuhiro Yamaguchi, Hiroyuki Arai

研究成果: Article査読

29 被引用数 (Scopus)

抄録

Aim: Yokukansan (YKS), a traditional herbal medicine, has been used to treat behavioral and psychological symptoms of dementia (BPSD). The present study is the first double-blind, randomized, placebo-controlled trial to determine the efficacy and safety of YKS for the treatment of BPSD in Alzheimer's disease (AD). Methods: A total of 22 sites consisting of clinics, hospitals and nursing homes participated. A total of 145 patients with AD were randomized. Active YKS (7.5 g/day) and placebo were supplied to 75 and 70 participants, respectively. The primary outcome measure was the 4-week change in total score of the Neuropsychiatric Inventory Brief Questionnaire Form (NPI-Q), an instrument that evaluates BPSD. Secondary outcome measures included 12-week changes in NPI-Q scores, changes in NPI-Q subcategory scores and total scores of the Mini-Mental-State Examination. Results: Four-week changes in NPI-Q total scores did not differ significantly between the treatment and placebo groups. There were also no significant differences between groups in 12-week changes in total NPI-Q scores, NPI-Q subcategory scores or total Mini-Mental-State Examination scores. However, a subgroup with fewer than 20 points on the Mini-Mental-State Examination at baseline showed a greater decrease in “agitation/aggression” score in the YKS group than in the placebo group (P = 0.007). No serious adverse effects were observed during the study. Conclusions: Our data did not reach statistical significance regarding the efficacy of YKS against BPSD; however, YKS improves some symptoms including “agitation/aggression” and “hallucinations” with low frequencies of adverse events. Geriatr Gerontol Int 2017; 17: 211–218.

本文言語English
ページ(範囲)211-218
ページ数8
ジャーナルGeriatrics and Gerontology International
17
2
DOI
出版ステータスPublished - 2017 2月 1

ASJC Scopus subject areas

  • 健康(社会科学)
  • 老年学
  • 老年医学

フィンガープリント

「Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル